Innovations at a Glance

• Conducting a phase 2 clinical trial for resectable non-small cell lung cancer comparing immunotherapy alone to immunotherapy with radiation therapy in the neoadjuvant setting
• Tested PTC596, an experimental compound, in combination with gemcitabine in mice with an aggressive pancreatic cancer, extending survival three times longer than with a single standard agent
• Led a phase 2 clinical trial treating patients with advanced, metastatic esophageal cancer with pembrolizumab, an immune-system boosting drug, resulting in regression of tumors in some patients

• Developed a closed implantable convection-enhanced delivery system to facilitate chronic infusion of topotecan with gadolinium to target glioma cells
• Conducted a study showing how high-fructose corn syrup fuels the growth of colon tumors in mice and demonstrated a potential strategy to block excess tumor growth

• Launched a phase 1b/2 trial to test whether nivolumab, with or without anti-IL-8 therapy, combined with a short course of ADT, promotes anti-tumor immune responses that prolong time to disease relapse for castration-sensitive prostate cancer

• Developing a vaccine in preclinical studies that could effectively train the immune system to recognize and attack cancer cells with mutations common in Lynch syndrome
• Demonstrated in a mouse model of lymphoma a novel engineered system to deliver immunotherapy from bacteria, leading not only to complete regression but could also treat distant tumors

• Developed a powerful set of scientific tools in collaboration with the New York Genome Center to track the molecular evolution of cancer

• Exploring the use of APX005M, an antibody targeting CD40, in combination with standard chemotherapy to stimulate an immune response in sarcoma